Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International journal of clinical practice

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1742-1241.2008.01938.xPMID 19166443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coronary drug project.

  2014cited by this paper
• The safety of over-the-counter niacin: a randomised, placebo-controlled blinded trial

  2010cited by this paper
• Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

  2008cited by this paper
• Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.

  2007cited by this paper
• Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

  2007cited by this paper
• Safety considerations with niacin therapy.

  2007cited by this paper
• Validation of a questionnaire to assess niacin-induced cutaneous flushing

  2007cited by this paper
• Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

  2006cited by this paper
• Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.

  2004cited by this paper
• The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

  2003cited by this paper
• Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

  2002cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

  2000cited by this paper
• Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies

  2000cited by this paper
• Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

  1998cited by this paper
• Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

  1998cited by this paper
• Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase.

  1998cited by this paper
• Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

  1994cited by this paper
• Types of Change in Coronary Stenosis Severity and Their Relative Importance in Overall Progression and Regression of Coronary Disease

  1994cited by this paper
• Hepatic toxicity of unmodified and time-release preparations of niacin.

  1992cited by this paper
• Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

  1986cited by this paper
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.

  1985cited by this paper
• Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man.

  1979cited by this paper
• Clofibrate and niacin in coronary heart disease.

  1975cited by this paper
• Serum creatinine and drug half-lives in renal failure.

  1972cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• The Coronary Drug Project

  1972cited by this paper
• The coronary drug project.

  1972cited by this paper
• National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report

  year unknowncited by this paper

• Kegiatan Pemeriksaan Kadar Kolesterol pada Petugas dan Karyawan SMA Santo Yoseph, Cakung

  2024cites this paper
• NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

  2023cites this paper
• Dietary Micronutrient Status and Relation between Micronutrient Intakes and Overweight and Obesity among Non-Pregnant and Non-Lactating Women Aged 18 to 49 in China

  2022cites this paper
• Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial

  2022cites this paper
• Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

  2021cites this paper
• Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels

  2020cites this paper
• Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes

  2019cites this paper
• Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

  2019cites this paper
• Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system

  2018cites this paper
• Niacin for primary and secondary prevention of cardiovascular events.

  2017cites this paper
• Definition of a tolerable upper intake level of niacin: a systematic review and meta‐analysis of the dose‐dependent effects of nicotinamide and nicotinic acid supplementation

  2017cites this paper
• Epidemiology and management of hyperlipidemia.

  2017cites this paper
• Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons

  2016cites this paper
• Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics

  2016cites this paper
• Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.

  2016cites this paper
• Management of residual risk after statin therapy.

  2016cites this paper
• Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

  2016cites this paper
• Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

  2016cites this paper
• Hypophosphatemic effect of niacin extended release in ischemic kidney disease

  2015cites this paper
• Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.

  2015cites this paper
• Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery.

  2015cites this paper
• Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials

  2015cites this paper
• Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

  2015cites this paper
• Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.

  2015cites this paper
• Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements

  2015cites this paper
• Effect of Niacin on FGF23 Concentration in Chronic Kidney Disease

  2014cites this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cites this paper
• Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies

  2014cites this paper
• Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction

  2014cites this paper
• Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

  2014cites this paper
• A multiple ascending dose study of CSL112, an infused formulation of ApoA‐I

  2014cites this paper
• Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

  2014cites this paper
• Nicotinic acid: a lipid-lowering agent with unrealized potential

  2014cites this paper
• Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?

  2014cites this paper
• Mechanism of action of anti-hypercholesterolemia drugs and their resistance.

  2014cites this paper
• Niacin, an old drug with a new twist

  2013cites this paper
• Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice

  2013cites this paper
• NIACIN AND NIACIN / LAROPIPRANT COMBINATION: OPENING NEW HOPES FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES WITH FEW NOVEL ACTIONS

  2013cites this paper
• Extended‐release niacin/laropiprant for lipid management: observational study in clinical practice

  2013cites this paper
• A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs

  2013cites this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cites this paper
• The role of niacin in lipid-lowering treatment: are we aiming too high?

  2013cites this paper
• Lipoprotein(a), cardiovascular disease, and contemporary management.

  2013cites this paper
• Effects of phosphate binding with sevelamer carbonate on cardiovascular structure and function in patients with early chronic kidney disease

  2013cites this paper
• HDL functionality and LDL quality : the influence of obesity, obstructive sleep apnoea and pharmacological intervention

  2013influential citation
• Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II

  2012cites this paper
• Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

  2012cites this paper
• Safety and tolerability of extended-release niacin with laropiprant

  2012influential citation
• Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

  2012cites this paper
• Niacin—A Critical Component to the Management of Atherosclerosis: Contemporary Management of Dyslipidemia to Prevent, Reduce, or Reverse Atherosclerotic Cardiovascular Disease

  2012cites this paper
• Nicotinic acid: clinical considerations

  2012cites this paper
• Niacin: The Evidence, Clinical Use, and Future Directions

  2012cites this paper
• Effectiveness and safety of laropiprant on niacin-induced flushing.

  2012cites this paper
• Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

  2012cites this paper
• Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

  2012influential citation
• Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication.

  2012cites this paper
• Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?

  2012cites this paper
• Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

  2012cites this paper
• Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus

  2012cites this paper
• Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

  2012cites this paper
• Drugs that affect lipid metabolism

  2011cites this paper
• Tarek Ahmed bw.indd

  2011cites this paper
• The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids.

  2011cites this paper
• Optimal pharmacotherapy to combat the atherogenic lipid triad

  2011cites this paper
• HCV and the hepatic lipid pathway as a potential treatment target.

  2011cites this paper
• Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.

  2011cites this paper
• Biological and pharmacological roles of HCA receptors.

  2011cites this paper
• Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

  2011cites this paper
• Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study

  2011cites this paper
• Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products

  2011cites this paper
• Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

  2011cites this paper
• Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises

  2011cites this paper
• The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease

  2011cites this paper
• Extended‐release niacin/laropiprant lipid‐altering consistency across patient subgroups

  2011cites this paper
• Emerging targets for the treatment of dyslipidemia.

  2011cites this paper
• Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters

  2011cites this paper
• The facts behind niacin

  2011cites this paper
• What restricts the clinical use of nicotinic acid?

  2011cites this paper
• Lipoprotein(a): current perspectives.

  2011cites this paper
• The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.

  2011cites this paper
• Gender-specific aspects in primary and secondary prevention of cardiovascular disease.

  2011cites this paper
• A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

  2010influential citation
• A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin

  2010influential citation
• Correlation between high density lipoprotein-cholesterol and remodeling index in patients with coronary artery disease: IDEAS (IVUS diagnostic evaluation of atherosclerosis in Singapore)-HDL study

  2010cites this paper
• Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care

  2010cites this paper
• Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.

  2010cites this paper
• Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia

  2010cites this paper
• Binder blinders-niacin of omission?

  2010cites this paper
• NIACIN, AN OLD DRUG WITH NEW PERSPECTIVES FOR THE MANAGEMENT OF DYSLIPIDAEMIA

  2010cites this paper
• Efficacy and safety of extended‐release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

  2010cites this paper
• A case report of a diabetic woman with very low HDL cholesterol.

  2010cites this paper
• Recent advances in preventing cardiovascular disorders by managing lipid levels

  2010cites this paper
• Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia

  2010influential citation
• New combination drugs in lipid management

  2010cites this paper
• Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

  2010cites this paper
• [Advances in cholesterol-lowering interventions].

  2010cites this paper
• Pharmacomodulation of High-Density Lipoprotein Metabolism as a Therapeutic Intervention for Atherosclerotic Disease

  2010cites this paper
• Do We Know When and How to Lower Lipoprotein(a)?

  2010cites this paper
• Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

  2010cites this paper
• Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.

  2010influential citation